ࡱ> tvs#` W=bjbjmm 4@ <```8d,y!x444hhk.  $"hY% 9kk @0h(3!V6 ( &`^*6I!0y!%%%\0" ' vdy! D  NSTEMI INITIAL DOSING GUIDE (Referenced Version) This dosing guide lists initial drugs and doses that should be highly considered based upon recent clinical practice guidelines, medication package inserts, and emerging evidence. WEIGHT AND CREATININE CLEARANCE Determine patients weight (kg) Determine CrCl ml/min = (140 age) X weight (kg)/(serum creatinine X 72) multiply by 0.85 if female ORAL ANTIPLATELET AGENTS ( Aspirin: 162 mg to 325 mg non-enteric chewed initially then 81 mg to 162 mg daily (or 162 mg to 325 mg daily after stent implantation). ( Clopidogrel: Loading dose 300 mg to 600 mg orally, then daily dose of 75 mg orally (Withhold for 5 days if CABG is planned; for BMS and DES ideally continue for at one year) ANTICOAGULANT THERAPY ( Unfractionated Heparin: Bolus: 60 U/kg IV (not to exceed 4000 U) Infusion: 12 U/kg/hr IV (not to exceed 1000U/hr) to goal aPTT 1.5 to 2.0 times local reference standard; check PTT in 6 hours and adjust heparin as below.  (Continue for 48 hours or until PCI) If PTT < 1x control: re-bolus 60 U/kg (max 4000 U) and increase infusion by 2 U/kg/hr PTT 1 to 1.5x control: increase infusion by 2 U/kg/hr PTT 1.5 to 2x control (approx 50-70 sec): no change (therapeutic range) PTT 2 to 3x control: decrease infusion rate by 2 U/kg/hr PTT > 3x control: stop infusion, recheck PTT in 1 hour, follow algorithm based on repeat PTT ( Enoxaparin: 1 mg/kg subcutaneous every 12 hours (if CrCl < 30mL/min, give 1 mg/kg every 24 hours) (Continue for the shorter of the duration of hospitalization, 8 days, or until PCI) ( Bivalirudin: Bolus: 0.1 mg/kg IV Infusion: 0.25 mg/kg/hr IV (caution if CrCl < 30 mL/min) (Continue for the shorter of the duration of hospitalization, 8 days, or until PCI) ( Fondaparinux: 2.5 mg subcutaneously once daily (avoid if CrCl < 30mL/min) (Continue for the shorter of the duration of hospitalization, 8 days, or until PCI) GLYCOPROTEIN IIb/IIIa ( Eptifibatide: Loading: 180 mcg/kg IV bolus Infusion: 2.0 mcg/kg/min (reduce to 1.0 mcg/kg/min if CrCl < 50mL/min) ( Tirofiban: Loading: 0.4 mcg/kg/min for 30 minutes (reduce to 0.2 mcg/kg/min for CrCl d" 30mL/min) Infusion: 0.1 mcg/kg/min, reduce to 0.05 mcg/kg/min if CrCl d" 30mL/min) ( Abciximab: Loading: 0.25 mcg/kg IV bolus (reserve for patients with planned PCI within 12 hours) Infusion: 0.125 mcg/kg/min IV (Continue for the shorter of the duration of hospitalization, 8 days, or until PCI) EndNotes     PAGE  Page  PAGE 2 of  NUMPAGES 2  Anderson JL, Adams CD, Antman EM, et al. ACC/AHA 2007 guidelines for the management of patients with unstable angina/non-ST-Elevation myocardial infarction: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the 2002 Guidelines for the Management of Patients With Unstable Angina/Non-ST-Elevation Myocardial Infarction) developed in collaboration with the American College of Emergency Physicians, the Society for Cardiovascular Angiography and Interventions, and the Society of Thoracic Surgeons endorsed by the American Association of Cardiovascular and Pulmonary Rehabilitation and the Society for Academic Emergency Medicine. J Am Coll Cardiol. 2007;50:e1-e157  Anderson JL, Adams CD, Antman EM, et al, 2007, e 37.48.  Anderson JL, Adams CD, Antman EM, et al, 2007, e 37.48.  Anderson JL, Adams CD, Antman EM, et al, 2007, e 37.  Anderson JL, Adams CD, Antman EM, et al, 2007, e 37.  Anderson JL, Adams CD, Antman EM, et al, 2007, e 37.  Anderson JL, Adams CD, Antman EM, et al, 2007, e 37.  ADDIN EN.REFLIST   Anderson JL, Adams CD, Antman EM, et al, 2007, e 38.  Anderson JL, Adams CD, Antman EM, et al, 2007, e38.  Anderson JL, Adams CD, Antman EM, et al, 2007, e38.  ADDIN EN.REFLIST  ________________________________________________________________________________________________________  Copyright 2008 by the American College of Cardiology. This content is owned by the ACC. A person accessing it may print the material and use it for his or her personal, institutional, non-commercial reference. Other terms and conditions for use may apply, particularly for comme349E( IJjVjVB1 hO@hr CJOJQJ^JaJ&h_C6B*CJOJQJ^JaJph&hp6B*CJOJQJ^JaJph,hFhp6B*CJOJQJ^JaJph2hFh_C56B*CJOJQJ\^JaJph,hFh_C6B*CJOJQJ^JaJph#hhthht5CJOJQJ^JaJhht5CJOJQJ^JaJh<hr 5CJOJQJhr 5CJOJQJhle*5CJOJQJjhle*U4 ( 4  G 0^`0gd /gdr ^gdr xgdr x-D@&M gdr x@&gdr -D@&M gdr 7$8$H$gd_C$a$gdht $@&a$gdr @&gd (5V=(   / 0 4 5 6 A B C n s ųšŒthšXņtIhO@h /CJOJQJaJhO@hr 5CJOJQJaJh /CJOJQJaJ#jh /0JCJOJQJUaJhr CJOJQJaJhhr CJOJQJaJ"hO@hr 5>*CJOJQJaJ" johO@hr CJOJQJaJhO@hr CJOJQJaJ(hO@hr 5B*CJOJQJaJph,hO@hr 5B*CJOJQJ^JaJph       " $ % H P μﭛxjZNZBh /CJOJQJaJhr CJOJQJaJhO@hr >*CJOJQJaJhr CJOJQJ^JaJ hw-hr CJOJQJ^JaJ"hO@hr 5>*CJOJQJaJ" johO@hr CJOJQJaJhO@hr CJOJQJaJ#hfJh /CJH*OJQJ^JaJh /6CJOJQJaJ&jh /0J6CJOJQJUaJhO@hr 6CJOJQJaJ =>?@AѭzjVD2"hO@hr 56CJOJQJaJ"hO@h /56CJOJQJaJ&jh /0J6CJOJQJUaJhO@hr 5CJOJQJaJ"hO@hr 5>*CJOJQJaJ" johO@hr CJOJQJaJhO@hr CJOJQJaJ)hO@hr B*CJOJQJ^JaJphhfJhr CJOJQJaJhO@hr 6CJOJQJaJh /CJOJQJaJ#jh /0JCJOJQJUaJ b # @eHgdU_ ^`gdr  `^``gdr  gdr gdr   7$8$@&H$]^gdr   7$8$H$]^gdr 0^`0gdr ABMQVfhp+E}n\J8"hO@hr 5>*CJOJQJaJ" johO@hr CJOJQJaJ"hO@hr 56CJOJQJaJhO@h /CJOJQJaJ&jh /0J6CJOJQJUaJhO@hr 6CJOJQJaJhO@hr CJOJQJaJhO@hr >*CJOJQJaJhhr CJOJQJaJhr hr >*CJOJQJaJ"hr hr 5>*CJOJQJaJhr hr CJOJQJaJEFHI\^`bdf}q}aQBhr hr CJOJQJaJhO@hr 5CJOJQJaJhO@hU_5CJOJQJaJhr CJOJQJaJhO@hr >*CJOJQJaJ"hO@hr 5>*CJOJQJaJ" johO@hr CJOJQJaJhO@hr CJOJQJaJhO@hr 6CJOJQJaJhO@hU_6CJOJQJaJhU_CJOJQJaJ&jhU_0J6CJOJQJUaJb,Hi|gdLgd /`gdr F`FgdU_ gdr  gdr  n^`ngdr  `^``gdr  ^`gdU_ bx@&gdr -D@&M gdr fx*2BGH߿߯o]K;hO@hr 6CJOJQJaJ"hO@hr 5>*CJOJQJaJ" johO@hr CJOJQJaJhO@hr 5CJOJQJaJhO@hU_CJOJQJaJ#jhU_0JCJOJQJUaJhO@hr CJOJQJaJhO@hr >*CJOJQJaJhr hr 6CJOJQJaJhr hr >*CJOJQJaJhr hr CJOJQJaJ"hr hr 5>*CJOJQJaJHJSghjkdzxh[KD<8<8<8<h;H;jh;H;U hr 5CJh /hfJ5CJOJQJaJh /5CJOJQJaJh /hr 5CJOJQJaJh /h /5CJ h /5CJh"qhr 5CJhhr 6CJOJQJaJhO@hr 6CJOJQJaJ'hU_hU_6CJOJQJaJmHsH#jhU_0JCJOJQJUaJ'hU_hr >*CJOJQJaJmHsH$hU_hr CJOJQJaJmHsH3m gd /gd^h&`#$`hgd^ hh]h`hgd^ &`#$gd^ 0^`0gdfJ  3¯¯žzk[kPh /hU_mHsHh /hU_6CJOJQJaJh /hU_CJOJQJaJ$h /hU_CJOJQJaJmHsHjhU_0JU h^h%D h^hU_0JCJOJQJaJ%hTp0JCJOJQJaJmHnHu)jh^h^0JCJOJQJUaJ h^h^0JCJOJQJaJhU_ hU_0JjhU_0JUh;H;"2345\lmnoKL^`abįxdxQ$hU_hU_CJOJQJaJmHsH'hU_hU_5CJOJQJaJmHsH(jhU_hU_5CJOJQJUaJ$hU_hU_CJOJQJaJmHsHhU_hU_CJOJQJaJ)jhU_hU_0JCJOJQJUaJhU_jhU_0JUh /hU_mHsHhU_CJOJQJaJmHsH$h /hU_CJOJQJaJmHsHa T=U=V=W= 0^`0gdfJgd%D 0^`0gdU_gdU_gdU_gd /bc  ٿp\M>hqh%DCJOJQJaJh%Dh%DCJOJQJaJ'h /hU_5CJOJQJaJmHsH$h%Dh%DCJOJQJaJmHsH$h /hU_CJOJQJaJmHsH'h /hU_5CJOJQJaJmHsH(jh /hU_5CJOJQJUaJh%DCJOJQJaJmHsHjhU_0JUhU_CJOJQJaJmHsH$h /hU_CJOJQJaJmHsHhU_rcial purposes. For more details, please contact the ACC in writing. This material is intended for reference and does not represent ACC policy. This content is not endorsed by the ACC. If any modifications are made to the content or layout of this material, all representation of the material as derived fromACC or NCDRshould be removed. <T=U=V=W= hr 5CJh;H;hU_hqh%DCJOJQJaJU2:pr BP/ =!"#$% ]Dd-xy>  C Ab']޷dRq @mB]Dn\޷dRq @mBPNG  IHDR HsRGB pHYsod\IDATx^ ]E t@$MQ Ȩ62mle2cP`۱ndП<  Q 侯u׭93'(7SjժUkUU˖-i3666226::I::::6|dy_/y>-~{/گc# զO൛O[gu6bN{4Di+`r54 CUe+ T(PQ(F[U DvB?AcRP-^믯~T&' (%-]2{]c߭Px4G/n&+J\E* H֕GRjIЮ45d3-wNE B ⃟@gZJ7kfmM>{ʌ&甴HxE* 4@Lf^uuIHP A $܎ztOX9Ip@Bpij&N]s{=y ݯJT(PQ@ Q1s;K}\4NOPAEǼQ%'!T%MZiՍwsΖ|xlILX)CNE* 4@#]HWȭyϝy|٥iֳFtTK~[>6IR!-%3Ƶ]RSUY##[4k3ҚӠ*QQ@E-RuVw^rg_L{Izy I+IDm%$D.'9]h7Y|yvLIQ(PQ@E(<!Mu=SAy<~PE uwUۀ' @X}ƔN؜#N+\E* @sD2r}ddERJaҙJ O}<*m3ĭT(PQFfʣfGS߼bT $wSF]%W * ))\[ɧ~vӜ(bOv_{BXq$?l+ T("P򘰥cgIaoMRCYZi99ф*OR5[Q KFT~iJ"KiWS=]{*ikړX[2sձzG|MQ<,S͡ZMI/[Bvm. \Ջaa95LU* `h<A.SsH| :,k3m^8:G}ѭ|0X}* T(PQ#h&R= D^n/輄8o}ѻ[է@E:E ?97 ϣ946~Fj "_ё[ GRU* c`@u'=:}HņtXD|C{0Qµ@EAqeP|N%" MIAKnAe[)§Cf%+GLUz=rP(|ǥ!?})啪X-l/*KVu w˫GgG_L\^NDvX˓6?glfQ$[tWϾ%mv#M㟂2i4\=j&+$lWra9 c-&x|W{SZ4iKLjb_`NH4HI+y9)9,7//%s >+Ѐ,[qJvdw#%*ntr5d)RUK϶[HF8jNnP=5vn.ZXOnlSзVUH'{{? -sL~ww^N'}}?|mmPo?f G;UJ-Ub;OcK,y衇D_W&~駞bmdZ{>r-yjQOM7:"eG6{tԽJ貗_FCokXPCUںZY#OdDm:5?zNiݭ˃ѩ$W]u⯱ίywe^(/@Cʙ C )?@կ~΀?>(}3C )&x&:EP'|^\:u7hɓ'\sͭt+?Ҹ_QjX|r{שm҃?O=IVX`]O9v.Hdweրv4ï򗿜;wndinԩ^xaqWl2$ SN)*[%׿ / }ȵD ~n;qK7CKp)l}A¢Bb Ri8#Aͺ^I̙wdҵdUM C J*BI3k!޶ ۟ \JbK_A׺D~~;.RCdQ\=a?57WhzmT@cg@_% }A.X^|g?[#n9ڎulR t.;bҔ(Sbm2 \=\Vm0X[k5)`NV`&̍f񀼳p#/.E:eIQYdJ[8˷94H%NL#μ`ԠxU'fDҬ.儾f{mfy, XcZz Td= ՕUI$+W{y1ERvfV%;;ZH$4l%}EEs U5Q;a+X>[$$S=I@D?y|k4: h y9ꨣlPVZWKO ' # &굅@_]83XQU1Kp}fl ʹ,d $6:k]N7L$[)>YĦ2|hR[(MthGf淿m3Cog-zoEj7EL"#+@7CX@3!td5*ѩҹPSTһo~E< R, az[O#\_|Uf ̛ٳgGJ𤈣n2hȚ.fM*0ۏMQ#I}ZV"ގPk:Á8Xd8ȥW6k+XY*H'|R_6h}BTH HguL~oW8 h"iC%Zo2Ј6R$֜@e{dDjtVAd-aeD%E ۍDX#:Izy:{a^% '|2_#L?l#?`^)Bџ^<6.P%AWF_ώ\l "W a<ʆr< (怟c&N鰕MK9HzLf)S,/O%#hl8VYQ dbKN>OX{& .Wo6ENuc @ ԀZl*$x8묳 cD6ȶ(tVGZ y$s|2$g.0b(XXg}0|䊟pn0xpwن1+oۮ>Uuf遖Ȁ w9G2$k1ߒ PlX@Q>Zg)<M AnK!6/tCԓ8@XKdfE!/Y-Pnno?eh]&pDc'>nL.5@y\qMk2ab<#޳':/8`-a{^C,L}Jy9QIO>$ ϚwBB~vॡ?DWa6Z>FT$r /<@,\4mSRZQmkhL)V˃)n{dCbNrfoteT4DI B{0:FQh_WԡA6a5v$cU$-$ަ>ܢ_qQ+GT [E/N;.'KbMYO%_\1jd4P=0kJsUԑ9)jqK~MZ=QG\&\A |+aL N5Â&T(pIL9:WV Pg!K7D:XiJC9ğ(,DǑU€wJ&r%FR1zaX X9eG1FP  &W6.ݶ+Z@vүs%l|r˩7oEbP@͡I7,άT" xрС>"lGvrdmHލق0^L5?F,p=Ca r=Zd`&K␜ -vXj} ݉<=VA N'q)DUv l w)h_a<9aɱ2,0*.ZC":XuCF+zف&+]$>:_$,J4jS&#$h%GWl_ގ A*S "4] d+7dW!*![9;>wlܼ:"&gi  |iwȅ$٪HTل胙 Ca/L ${/x=VNVmԐ7 GUy1mi΄w<y6S6Əқ(#Il=Z6&EZeoAh L=GG{U$5~\o'B,R`L(_>h&z(vy/-7BNO8UTz1S) Sai/-08hyi%jӦ}Y#fC`K@:w4H 1c&e+h@$ޑB@ڌ^$ɪa QtvWR#z9%c5 b*=Y;L;d"]tO8LXmDj&$K|~BXpŸj:^}"sl(].k&}@*O<ކxX^UX Ay$ w hp K޼?h[z+u;F€ܻkR&_<+]>Q.yDv#]5Xzw s!+:D(=vnрY7oe]&V~EbUPA`R{EߐV5 FXINpm,y%|'5/]/"~J&)lG*0ut,~Ds}&[vF#j./|a=l1#(ǻƨM|q ':9]@؛.!i&U) m=t+HD|0 6ayQbNHa% :֧f"w>U'[; 6cnG&Fjþr8@dW12Wk=p'g=v5\aA?1ǜtIW.\2C#ȫUzF)w{,:jHx8 ՁovzւdžǿeJ-K$e]yЎqo *jꚫpgg?@ׯx_`⤳;L!MN9z# W|O<zZ.1F#B:䓷jqmG*M^rYQ,+,'j}! KGf0/``9XUɎP U|_CwBW#6h=Ix3mlAM6}?w˽kk޸w)C\9.Ş}jӠMdm͑$bc]vQDS}Ug}WёҨ#i:[ً>8eJӡ]HlDwznqzDR!Hύ8h>v? si[_أ&f'J ex7́5.q8@FIֶܳävzo]\O&f5aUՀ, Z(Щ ܈9sD CR='ax1#7?KMV:\\|~)Yrj =ŧEX'yW-oEh;e-8=7hTq[D\rqp 3Kn<Wɔwzz?/y$q]a,w.M/JbBp'lwi{Ȧ h3yntܡ,G5@q;[4:F.4/OY*GaڈV~wH7T}0.5WVpT7HF R5PWxiNOVaomнox߽o88{c<5wHDSJrh97aR;F__-d_zPUVX簋!62Z뫺`{b CNh՛%BD$#bW=D[l@[$ Ű>v CYX}%T@|rHtz>RrN{R//+8do96z6|-jotIҨ%\'(~ CvL :u6%YALYgV:5 MxsA(qW7<"*7^VC9ɨ' qPvYHqȠThR 2cu?ZTxMi45QKZ-}ohv=o RD2{WFrӦ+h.tkk%eHyu&mu#L"d=lJe|?wөZr39^J80 $T./vaTK-%6el,;Ast4IwB>l*FbNn6+-ڲ\av^N =!!W>7x)̗ MzDt:?);ˈkC[M 8::ȓk=F!-7@ɗG3a~7v΍ZKE&k1HLJ hI0  7Q;wy++>f?2o%^NEDУ-!Na6GĔ%ow0cØa?U;|җ*mɹaeVQ3-:%mC1m]ZwQ!:Wv@.ہauIv*S% )PDS';0h#d_^5*y0O KܪħT$+5_;L'1}je/an2j[JޗʹLM65 &oz zڤFW P"Kwiթ *৿(LKK[uFw7܃ߣiL9R^Fn.] k*&<ہ΁K)= "mMHhޕ܎ngye12v*A+CX3g4l=>^1{ۨNAVWyvG_Ni}k^849J_c[ 1B]bu0$֐;pZ0w209Yfҡ۠1d%/t6RNvcJ-îۤUo~}jL:V>l3GV4듆_xk6t=žh ڔ3 HwC",zL]\o+ig?] XU`qz;sIQdAJVźJFa+kxxdùt-io_xGbmK\;i@X±%FM?[FԻ \gBҴΓ ! J:O VU* tV褩3f?&$כJngǟKE?NR"KP=vC)Fܚ,(voo8Dsf{ӗV<k}jt((leG];δ]wr.q?TVx8ѪrC외}FY>FWz)|wpluH!D[-mHЕyG]Ք>L>!"\NuˏO?}d%xGh}ru=Kpn… M#q[T.V?m (^]:BnQpP`7߼A6 y,_ uds}ktIW?N3g6v߼x UJ2<)$q|MH n8RۑHa݀kOÃAo<-Kp;nf!zS~((lnp،>yPU+TI@86H=wƪ< $ZnX [X$jWRQUT+Ԯ)x7eʔ! ySRٳ=Lvꩧm(wuGqD={T.y̭m|JeG8֫ɕOۗuf[س|/KW`=ϷP<;Y1^PII,~h7;W.46RrVrnii63>z 5k'Jy9pU( @ocnl>IT݆^Zx0['ߪ@ D-rRTMz!%ڎ?x$ͳԒɦncg$VjVIXC{V֋ Fq4I'dG!`Aܪbڡ@I!ӧsz?!ϊ(<~]u {;7^7L6 Y/3q,*؝Yvd |TX|"熯Ď;8y,K9fj(](u~&JUR.'s7!+r=>t/qZW/8 &7K"xu-Wתw|H|:ÚMcBunrTw2/<n[uM7DM$E)9X!W^ 1y[CBur/%Ri';y'G ?G-]tEhumo q0r.h s-d=ʹ_%S׵EmS)͟/{9Q#)ԓ%Zlemg67x"RƾQP_#ՠ#E~j\8#I.̸QV }v[KO;x৾Y6GqSdx1WatHe{=m,ՎWӎYʠ=Ur#;-5vѕ_ W%I4#]LǮ\P[UOD&W7ب^ ʭW_"x1zѯΜۖݕrgke(ZUr"-6(oVPB޴ vز'Ua.2./QϺ^N,~r֓V#6C t[m/Y;͑J뗘Ȓ%һ=@#C_O5O~iUJ*,1uNo\L?~&TEdb,35{s!ЯIhhSаWQ8E֠LqQ[vHQn;,UdXn?|}GKYnq w 3U(PQ`@<(XaGL~ٛtX}VJ;U+ T(= tRy$>Gz#P󓿸ɹIRu&?÷=W+ T(0򈒥l|-9菚! * tSP9ivɫNtO7vGgT* TZ tNyC}l*tƚ|qӰ>1 S!^Q@E@)OOH|'JRݑ߮o+6)i ႛ+>*}y7#p4̓1gi6NDLedhvx,6r0[B.܉.vmݘ[J<_ j҆ݍ!,D}l?|,5uf}i5x( HG#mL`rH_ܾTz8a"h4(& ̝- V1;5h1j4)|=T9uIOT].DQܮe9{^+'?ҠUr;aعY[F|=iROMlŪR/ z%,VQt7&02o*[D]h;4mRDUÄIHvryWz_EaNnF ps;bhMbn CkzṔXz|At\5sLn䢤,v 70JѨ@FNS Ip"޴VKtK f4뭸̊O-q]9e6P'8.U?>[AAӇ~.nvY|(ϽJz70ʨ½lԧI>h:O?ê`-0uSJ7Mo~y8=~&labeO9xWx#3?g?'f,LOooyX$qALܡKzu>;bz;CIHeL;B^x*oi~8ӳqa0ę+}_^6C˅$)="*A2fR)+F.~}^Ս,ʦ|\Z="V +EH/"%~Epk6XEgr=MUfV1SF|򓟔e [+oJ5$\^sw7m׃-^XM#d`Nϟ^d13Ͷ呇Z3nk}6!+Cr5+>n KJC* lٲzrA }>m6B/|20ғݣG rMxڲj$L#h9 gJd- ],8j4x5"AEI-<)EC@<&3|D%[˿OFL%hL)8.X*}JBM|c_\a%oBZAy¡^;kLj)1hzj5|ˤ_spP'`( fVp zryh^)hxryzE˿m/,y!..!g!7/b/3؈3&&8Y-`Fd&\a܃&I4/AbI}o #ZL]eu+vyIr5^nKHcu3ӫHW(eL ڇrȈCH%Ɨ%'֧Dg?8` 噙ɑٳg44' nЙ>x ċ.pm[" yhW]u`Io.!LXssK c}Tٞ.#h`"+iϐ_p*Ve/Wllx[CIJGyg#êW$Y'ESGLb:>Lz)r)hҘPzI'5p&x~ mg[1F(h$|Cr}x7#3GK # a&(cV XDZE"Ţ+o} [_EO?PR?V0i+Z 0(άXcݡ]߃zﵜ{T M0fV&^dn0GL+eyzk_b* "/O \IC~ 6b0-64@@SH_$"Y{^-{[>KaA P5 آ%Ces^|>wbAв*D&%{B0jM:=>r (斱ВgZvkxYsiJ"?Z[Sކa̠$u7c|`2&gv8W]o>sOZi.gqhdc Zxr#IshÊ({B.g'mK]ȝBj"5 KsxJIjf6ދke+/HZ 9I~ m3Thz%frQʃB)KTw* e[1FB'wDI :[")IR1x>A-({ErYXؘ"h ^##.*.Ё9Kg5XIXCN?;]~֫9Li;cPE')A'1lZ/qM݈e6Z)񄍇 iPb+l0)C{8s? _=w٠JJ`bM _|1\ia-"BCJ,$/l1;z;y#" ɝ{arx'%,F7t^^x!jCݱ;f)e J:`b``rGSg_njMHcQ 4k3P)TOƳ*+)hRLF d&fxB#w@Q,HyWa;5QϘ )=S/}Z cw[O͕}%)8J>.C٪:C)d%D!1Ic?1Q^m)e3CF7f<)|<%FaG*PҐ]CPTGjlΪXij,Bt96^ƍ"6 *%[Ldll!BJE5?R~\^!;p1bpWyDMNoZKjHf=` gg[D#*E |,Ij @i c Ll[-#TDODN /D 1vo!_6I1-0OCԶֽ؉#\/S=@Y]vQru"!jBҡ@ھlv+خ{шͽlGᬽo`k>MKF[KyV/Ba^)Y,#y|E*#(/GwI bAAaůh4vFHbj6z9O*"2 ᳼(;. ĺ8vr:Ě=$kZPIkȈTTIǣTv()]⏡Aߐjh($x)5OagK/8XP$BQ[vx4P`$EyNQg`[ݱg%әRi)N0Y-0mQ2ʃ %`<3=끿 [fm`~6x~L?@R82Mɑ~~ k<m߱ښ/$ "8#]mz; -e99wZZvxA0Cq [oMӧ;yGe&;As{a 4AEp |84Jy-!V@{^s~q 5T|L^W/>6Po{pMhWXQLh-| $>$ޤ$2Y5:Q/.B:Fja!2`_C(Gi/ ͡ 8gΆD{DŽPB*s84| Ev`2P2zC06mz*ue]!c$l(T+it_4M#xh,X7UHCD* IѪ_p/:0- Ҿ/F|x1RF@E}bwH#(z+e.4Qxv6b6to~adiv hBg{Z/@d[6Rz#؎0b=8}z.]xyoU66YNlG/iސl)t Nq<-MALJquM[ -/irj 9"xXa#6RTͮm7 `ᤰ6|Y)Fza}z7.W[!r:2 ܗ)A+_N2M HUᤍm̜9S!2B 42Ztɶ"+q&*䑳O?IMyl<7V Wg+kF($75 ŝO#%Zt|C@Ʀj@EF-lHpYTeg+w&IENDB`@@@ r NormalCJ_HaJmH sH tH DA@D Default Paragraph FontRiR  Table Normal4 l4a (k(No ListROR r Heading-D$M gd 5B*ph4 @4 r Footer  !>>  / Footnote TextCJaJ@&!@  /Footnote ReferenceH*.)@1.  / Page Number<+@B<  / Endnote TextCJaJ>*@Q>  /Endnote ReferenceH*4@b4  (5Header  !/=E.g +e Y@4(4G  b#@eH1H i     3 m a 000000000000000000000000000000000000000000000@000@000@000@000@0Qh0 0h0 0@0@0@000p@0@0@0@0@0@0@0@0@0@0@0@0@0@0@0@0@0@0004(H   3 m j00x h00 h0 000000.00 00000 00 00 0 0 000$j00<$h00h00@0 00;j00 39j00j00@0@0 00 ;;;>( AEfHbW=  W=V= #%*57>!!CVWQQ8@0(  B S  ? OLE_LINK2 OLE_LINK7g !$9*urn:schemas-microsoft-com:office:smarttagsplace=*urn:schemas-microsoft-com:office:smarttags PlaceType=*urn:schemas-microsoft-com:office:smarttags PlaceName 82659"J S T g    3 " $ + , 2 5 \ ^ e f l o =?FGIcY[J h    3 2 5 l o Kc33     3 m ^a   le* /|4 (5;H;_C%DfJLU_HIfTpqhtp^r EN.InstantFormat8O EN.Layout,P EN.LibrariesRw<ENInstantFormat><Enabled>0</Enabled><ScanUnformatted>1</ScanUnformatted><ScanChanges>1</ScanChanges></ENInstantFormat>P<ENLayout><Style>JAMA</Style><LeftDelim>{</LeftDelim><RightDelim>}</RightDelim><FontName>Times New Roman</FontName><FontSize>12</FontSize><ReflistTitle></ReflistTitle><StartingRefnum>1</StartingRefnum><FirstLineIndent>0</FirstLineIndent><HangingIndent>720</HangingIndent><LineSpacing>0</LineSpacing><SpaceAfter>0</SpaceAfter></ENLayout>T<ENLibraries><Libraries><item>acc_dosing guides.enl</item></Libraries></ENLibraries>@ kq4 `@``$@`x@UnknownGz Times New Roman5Symbol3& z Arial7&  Verdana7Tms RmnQ Zapf DingbatsSymbol"1h8f8fvVvV!4 2qHX ?r 2NSTEMI INITIAL DOSING GUIDEChuck Greenfeld AdministratorOh+'0  $0 P \ ht|NSTEMI INITIAL DOSING GUIDEChuck Greenfeld Normal.dotAdministrator2Microsoft Office Word@@p@pvV՜.+,0 hp  Columbia MedCom Group ' NSTEMI INITIAL DOSING GUIDE Title  "#$%&'()*+,-./0123456789:;<=>?@ABCDEFGHIJKLMNOQRSTUVWXYZ[\]^_`abdefghijlmnopqruRoot Entry Fz&wData !]1TableP%WordDocument4@SummaryInformation(cDocumentSummaryInformation8kCompObjq  FMicrosoft Office Word Document MSWordDocWord.Document.89q